Yazan Abdeen, MD
Pulmonary Disease · Newark, NJNPI 1679983605
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,040 of the $44,045 with a category attached, or 63.7%. 37 manufacturers reported payments, led by GSK at 54.1% of the total. Reporting peaked in 2019 at $29,071 and has fallen 95.1% since, to $1,429 in 2025. Among pulmonary disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 358 payments — averaging $123.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$24K
- Grifols USA, LLC$5K
- Viiv Healthcare Company$3K
- Intuitive Surgical$3K
- Inari Medical, Inc.$2K
- Noah Medical Corporation$1K
- plus $6K from 31 others
What the payments were for
- Speaking & faculty fees$28,04064%
- Travel & lodging$6,02014%
- Food & beverage$6,88816%
- Education$3,0977%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 113 | $23,849 |
| Grifols USA, LLC | 20 | $4,882 |
| Viiv Healthcare Company | 1 | $3,400 |
| Intuitive Surgical | 1 | $3,000 |
| Inari Medical, Inc. | 9 | $1,861 |
| Noah Medical Corporation | 5 | $1,079 |
| Olympus Corporation Of The Americas | 10 | $1,038 |
| Boston Scientific | 5 | $726 |
| Electromed, Inc. | 53 | $686 |
| Johnson & Johnson | 1 | $552 |
| Inspire Medical Systems, Inc. | 14 | $411 |
| Sanofi | 20 | $354 |
| AbbVie | 15 | $279 |
| AstraZeneca | 9 | $251 |
| Actelion Pharmaceuticals US, Inc. | 12 | $229 |
| Boehringer Ingelheim | 19 | $221 |
| Genentech USA, Inc. | 11 | $212 |
| Pulmonx Corporation | 3 | $185 |
| Stryker | 1 | $168 |
| Regeneron Healthcare Solutions, Inc. | 5 | $166 |
| Sunovion Pharmaceuticals Inc. | 9 | $112 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Mallinckrodt Enterprises LLC | 2 | $39 |
| Mylan Specialty L.p. | 1 | $32 |
| Philips North America LLC | 2 | $32 |
| United Therapeutics Corporation | 2 | $30 |
| Insmed, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Circassia Inc. | 2 | $24 |
| Amgen | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Shionogi Inc | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Conmed Corporation | 1 | $13 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$20,924
- Prolastin-C Liquid$3,135
- ION$3,000
- FLOWTRIEVER CATHETER, S$1,734
- CT THROMBECTOMY SYSTEM KIT$1,734
- Prolastin-C$1,545
- ANORO$1,361
- Olympus Bronchoscopes$906
- Olympus Respiratory Accessories$906
- Olympus Capital Accessories$906
- MONARCH$552
- GENERAL PULMONARY$483
- Inspire$254
- CLOTTRIEVER BOLD CATHETER$168
- CHARTIS CATHETER$147
- ZEPHYR DELIVERY CATHETER$147
- ZEPHYR ENDOBRONCHIAL VALVE$147
- PULMONX CHARTIS TABLET CONSOLE$147
- TEZSPIRE$137
- FASENRA$137
How this compares
$44,045 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 262 | $188,002 |
| Dupixent PenDupilumab | 27 | $102,458 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 93 | $60,086 |
| EliquisApixaban | 40 | $29,133 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $9,033 |
| Wixela InhubFluticasone Propion/Salmeterol | 51 | $5,070 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 153 | $3,396 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $2,333 |
| Budesonide | 21 | $1,372 |
| Varenicline Tartrate | 11 | $1,002 |
| Montelukast Sodium | 137 | $820 |
| Azithromycin | 97 | $539 |
| Fluticasone Propionate | 36 | $370 |
| Methylprednisolone | 46 | $309 |
| Cefdinir | 27 | $304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $23,849 | $197,035276 claims |
| AstraZenecaBreztri Aerosphere | $251 | $60,08693 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Newark
- Richard MillerNewark$328K
- Christina MiglioreNewark$27K
- Pratik PatelNewark$16K
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.